TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34495437
Drug: Prophylactic anticonvulsant
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anticonvulsant use only in aSAH
Study: 34495437
Drug: Prophylactic anticonvulsant
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anticonvulsant use only in sICH
Study: 34495437
Drug: Prophylactic anticonvulsant
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anticonvulsant use for all patients with aSAH
Study: 34495437
Drug: Correct response
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correct response to AHA/ASA Guidelines on prophylactic anticonvulsants in sICH
Study: 34382717
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of French maritime pine bark extract supplementation (Oligopin) with enteral nutrition for 10 days
Study: 33221341
Drug: AB2 (affinity-matured
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB2 (affinity-matured recombinant Fab inhibitor)
Study: 36411968
Drug: PMC split-dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMC split-dose regimen
Study: 37533380
Drug: Trazpiroben 50
Normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazpiroben 50 mg
Study: 33462988
Drug: Trazpiroben 10
Normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazpiroben 10 mg
Study: 34805403
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydroxyzine and clowns
Study: 35193545
Drug: Enerisant 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enerisant 25 mg/day
Study: 35193545
Drug: Enerisant 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enerisant 50 mg/day
Study: 35193545
Drug: Enerisant 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enerisant 100 mg/day
Study: 35193545
Drug: Enerisant 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enerisant 5 mg/day
Study: 35193545
Drug: Enerisant 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enerisant 10 mg/day
Study: 34957992
Drug: Combined handheld
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined handheld ultrasound and fluoroscopy-guided corticosteroid injection
Study: 34957992
Drug: Conventional ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ultrasound-guided corticosteroid injection
Study: 36235865
Drug: FibreMAX (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: FibreMAX (two daily servings of 25 g of BARLEYmax®)
Study: 36235865
Drug: FibreGRAD (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: FibreGRAD (two daily servings with the amount of fibre gradually increased)
Study: 36235865
Drug: Control (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (two daily servings totalling 25 g of placebo product)
Study: 32140704
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplement 10 µg
Study: 32140704
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplement 25 µg
Study: 32140704
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 µg)
Study: 35925203
Drug: Non‐Ach (beta‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐Ach (beta‐3 agonists)
Study: 33512251
Drug: Honey-lemon spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey-lemon spray
Study: 33512251
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride spray
Study: 33715382
Drug: TR‐PH (fixed-combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR‐PH (fixed-combination tropicamide 1% and phenylephrine 2.5%)
Study: 35553560
Drug: Heat Therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat Therapy (HT) at 39ºC for 30 min/day, 5 days/week during 3 consecutive weeks
Study: 35553560
Drug: Heat Therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat Therapy (HT) at 39ºC for 3 weeks
Study: 32398160
Drug: Nitrous oxide/oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrous oxide/oxygen plus intravenous acetaminophen (NOO-A)
Study: 33493450
Drug: Anakinra (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (200 mg twice a day on days 1-3, 100 mg twice on day 4, 100 mg once on day 5)
Study: 32907433
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control with glycemic targets of fasting blood glucose (FBG) <130 mg/dL, postprandial BG <180 mg/dL, and HbA1c <8%, using a basal-bolus insulin regimen and frequent titration of insulin.
Study: 32907433
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose control with prior treatment (oral antidiabetic drugs) with no titration unless meeting rescue criteria.
Study: 34391759
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation therapy (LDRT) of 0.5 Gy to bilateral whole lungs
Study: 34251534
Drug: Oral irrigator
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irrigator + toothbrush (OI group, n=15)
Study: 34251534
Drug: Oral irrigator
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irrigator + toothbrush (OI group)
Study: 33827834
Drug: Active Communication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Communication Education (ACE) programme plus treatment‐as‐usual
Study: 33827834
Drug: treatment‐as‐usual only
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment‐as‐usual only (control group)
Study: 32168417
Drug: Ultrasound acupuncture
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound acupuncture (pulsed therapeutic ultrasound at 1 MHz for 5 minutes per point daily for 12 days)
Study: 35150943
Drug: Chitooligosaccharide (COS)
Normalized name: fructooligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitooligosaccharide (COS) 15 mg/kg
Study: 35218559
Drug: Terbutaline (TER;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (TER; 4 mg × day-1, n = 13)
Study: 36161487
Drug: Standard (control)
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard (control) treatment
Study: 36120781
Drug: 10-mg/d Donepezil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg/d Donepezil Transdermal Delivery System (TDS)
Study: 36120781
Drug: 5-mg/d Donepezil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg/d Donepezil Transdermal Delivery System (TDS)
Study: 36120781
Drug: Oral Donepezil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Donepezil (10-mg/d)
Study: 37602418
Drug: Topical repellents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical repellents
Study: 34192714
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (n=90)
Study: 35361636
Drug: Group biofeedback
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group biofeedback treatment, psycho‐education and treatment as usual (TAU)
Study: 35361636
Drug: Group biofeedback
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group biofeedback treatment, psycho‐education and TAU
Study: 32848365
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C 1 g administered 10 minutes after induction of anesthesia, 10 minutes before cardiac reanimation, and at the moment of sternal closure
Study: 32848365
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C 1 g administered
Study: 33883048
Drug: Breast milk
Normalized name: BREAST MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast milk oral care
Study: 34971214
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (pulsed transcranial and intraocular 1068nm near-infrared light)
Study: 32149424
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg APT‐1011 BID
Study: 32149424
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg APT‐1011 QD
Study: 33713384
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (3 g)
Study: 34238308
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day NMN
Study: 34238308
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day NMN
Study: 34238308
Drug: 1200 mg/day
Normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg/day NMN
Study: 35609974
Drug: Coated flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated flow diverter p64 MW HPC under single antiplatelet treatment (SAPT)
Study: 35609974
Drug: Bare flow
Normalized name: urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bare flow diverter p64 MW under dual antiplatelet treatment (DAPT)
Study: 34226917
Drug: Baseline models
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline models using five commonly used ML methods
Study: 36100795
Drug: IV 400
Normalized name: VPRIV 400 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 400 mg ibuprofen
Study: 36100795
Drug: IV 20
Normalized name: TPIV 200
DrugBank: TPIV 200 (DB17318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 20 mg tenoxicam
Study: 34384882
Drug: Continuous letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous letrozole (2.5 mg/day for 5 years)
Study: 34384882
Drug: Intermittent letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent letrozole (2.5 mg/day for 9 months followed by a 3-month interruption in years 1-4 and then 2.5 mg/day during all of year 5)
Study: 32114186
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment
Study: 32187503
Drug: 4D-calculated dose
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4D-calculated dose
Study: 35644931
Drug: Tradipitant 85
Normalized name: Tradipitant
DrugBank: Tradipitant (DB12580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tradipitant 85 mg b.i.d. for 9 days
Study: 33187948
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg oral amoxicillin before and after surgery
Study: 33187948
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg oral amoxicillin after surgery alone
Study: 35576560
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (patient education and exercise therapy using a mobile messaging app)
Study: 35576560
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (usual medical care with pharmacological treatment)
Study: 33864917
Drug: Oral hydroxychloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydroxychloroquine (400 mg once, followed by 200 mg/day)
Study: 33864917
Drug: Povidone-iodine throat
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine throat spray (3 times/day, 270 µg/day)
Study: 33864917
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc (80 mg/day)/vitamin C (500 mg/day) combination
Study: 33864917
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (12 mg once)
Study: 33864917
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C (500 mg/day)
Study: 34417274
Drug: 7-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day course of oral amoxicillin (according to WHO weight bands) provided by community level health workers (CLHWs) in intervention clusters.
Study: 34417274
Drug: Standard community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard community case management (assess and refer after pre-referral antibiotic dose) in control clusters.
Study: 35215507
Drug: Maternal hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal hemoglobin concentration 100-110 g/L
Study: 35215507
Drug: Maternal hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal hemoglobin concentration <70 g/L
Study: 35215507
Drug: Maternal hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal hemoglobin concentration >130 g/L
Study: 35215507
Drug: Maternal hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal hemoglobin concentration <70 g/L or >130 g/L
Study: 33368237
Drug: Structured delivery
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured delivery preparation education
Study: 33368237
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no structured delivery preparation education)
Study: 33270142
Drug: Cervical headgear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical headgear treatment for 2 years
Study: 32093635
Drug: High sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sensitivity for type 1 algorithm (ratio of type 1 to type 2 codes ≥ 4, or at least 1 insulin prescription within 90 days)
Study: 32093635
Drug: High PPV
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High PPV for type 1 algorithm (ratio of type 1 to type 2 codes ≥ 4, and multiple daily injections with no other glucose‐lowering medication prescription)
Study: 32093635
Drug: Optimized algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized algorithm (ratio of type 1 to type 2 codes ≥ 4, and at least 1 insulin prescription within 90 days)
Study: 32211908
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) injection
Study: 32289159
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily
Study: 35099359
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-i) with therapist guidance
Study: 35099359
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-i) without therapist guidance
Study: 35099359
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control group receiving unguided treatment after a delay
Study: 34289212
Drug: ConquerFear-Group (CF-G)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ConquerFear-Group (CF-G)
Study: 33494844
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake (936 mg/day)
Study: 33494844
Drug: Magnesium intake
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium intake (315 mg/day)
Study: 33494844
Drug: Phosphorus intake
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphorus intake (1350 mg/day)
Study: 33494844
Drug: Total calcium
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total calcium intake (1026 mg/day)
Study: 33494844
Drug: Dietary magnesium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary magnesium intake (331 mg/day)
Study: 33494844
Drug: Dietary phosphorus
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary phosphorus intake (1402 mg/day)
Study: 34687053
Drug: Reciproc Blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reciproc Blue (RCB) size 25, 0.08 taper
Study: 34687053
Drug: XP-endo Shaper
Normalized name: 2-acetoxy-1, 8-cineole, (+)-endo-
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP-endo Shaper (XPS) size 30, 0.01 taper
Study: 34687053
Drug: R-Motion (RM)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-Motion (RM) size 30, 0.04 taper
Study: 34687053
Drug: HyFlex CM
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Hyflex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyFlex CM (HFX) size 30, 0.04 taper
Study: 35852825
Drug: Electrochemical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrochemical treatment (EC) + AU
Study: 35852825
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (contaminated without any treatment)
Study: 39271521
Drug: Acalabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 100 mg twice daily
Study: 34083384
Drug: GPR84 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPR84 and FFAR4 agonists
Study: 33606782
Drug: Public health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Public health measures (masking, physical distancing, contact tracing app, willingness to take a COVID-19 vaccine)
Study: 33405082
Drug: EGCG150 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG150 (150 mg/kg EGCG)
Study: 33939887
Drug: Curcumin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin and other polyphenol extracts (turmeric, red clover, flaxseed, resveratrol) at a dosage of 3 capsules/day (296.4 mg phenolics/capsule) for 5 ± 2 days before surgery
Study: 33939887
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no capsules)
Study: 32819312
Drug: Folate-oriented tertiary
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate-oriented tertiary interventions including assessments of folate status and metabolism, folate intake guidance, and re-evaluation of folate status to ensure red blood cell folate level above 400 ng/ml before pregnancy.
Study: 33571817
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of urinary cadmium concentration (median = 0.20; 25th, 75th = 0.13, 0.32 μg cadmium/g creatinine)
Study: 34435371
Drug: MK-8507 200
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8507 200 mg
Study: 34435371
Drug: MK-8507 800
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8507 800 mg
Study: 33606754
Drug: Forearm intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forearm intravenous regional anaesthesia (IVRA)
Study: 33044849
Drug: Concurrent aerobic-resistance
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent aerobic-resistance (A-R) training
Study: 33044849
Drug: Concurrent resistance-aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent resistance-aerobic (R-A) training
Study: 33044849
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (CT) (both A-R and R-A)
Study: 32090730
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (open practices)
Study: 32090730
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment or placebo)
Study: 33547808
Drug: L‐PRF+IBB
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐PRF+IBB
Study: 32265255
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (IDet) plus short acting insulin Novolin‐R before three meals (RRR‐IDet plan)
Study: 33340081
Drug: PBMT (Photobiomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT (Photobiomodulation therapy)
Study: 33595486
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 μg/kg body weight) as an additive in peribulbar block
Study: 32553818
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GLS and ejection fraction
Study: 33933894
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg buprenorphine
Study: 32272516
Drug: HP/TAZ lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP/TAZ lotion (halobetasol propionate 0.01%/tazarotene 0.045%)
Study: 32677156
Drug: Autologous umbilical
Normalized name: Autologous umbilical cord blood
DrugBank: Autologous cord blood (DB17926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous umbilical cord blood (UCB) stem‐cell therapy
Study: 34185582
Drug: FDM-informed manual
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDM-informed manual therapy
Study: 34155501
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with capecitabine (1,000 mg/m2 b.i.d for 14 days) and intravenous cisplatin (75 mg/m2 at day 1, every 3 weeks)